Q2 FY2026 EarningsQ2 FY26 results beat consensus across the top and bottom lines, with revenue of $796.2M (+3.28% vs. expected $770.9M) and normalized EPS of $0.18. Specialty segment revenue grew 16.6% YoY, driven by the strong launch of CREXONT®, while Affordable Medicines revenue rose 13% YoY due to new products. Operating leverage and lower interest expenses resulted in a significant net income beat, though GAAP results remain impacted by antitrust litigation and opioid settlement charges.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Amneal Pharmaceuticals(AMRX) the Revenue is 796.2 M (+9.89%), Beat estimate;the EBIT is 192.65 M (+14.43%), Beat estimate;the EPS is 0.18 (+157.1%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.80B9.89%
0.77B6.40%
+0.03B3.49%
EBITExceed expectations
0.19B14.43%
0.16B5.47%
+0.03B19.90%
EPSExceed expectations
0.18157.14%
0.046833.16%
+0.1332190.30%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf